Rochester, NY 6/11/2009 1:08:40 PM
WFWS "After Market Most Active by Volume -NYSE" - Exxon Mobil Corp.,XOM - Dow Chemical Co.,DOW - Johnson & Johnson,JNJ
Exxon Mobil Corp. - Dow Chemical Co. - Johnson & Johnson
WFWS "After Market Most Active by Volume -NYSE" - Exxon Mobil Corp.,XOM - Dow Chemical Co.,DOW - Johnson & Johnson,JNJ
Exxon Mobil Corp.,XOM
After Hours: 73.84 0.00 (0.00%) 7:53PM ET
Last Trade: 73.84
Day's Range: 72.84 - 74.12
52wk Range: 56.51 - 89.63
Volume: 27,361,020
Exxon Mobil Corporation engages in the exploration, production, transportation, and sale of crude oil and natural gas. The company also engages in the manufacture of petroleum products, and transportation and sale of crude oil, natural gas, and petroleum products. It manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and other specialty products. The company also has interests in electric power generation facilities. As of December 31, 2008, it operated 16,286 gross wells. Exxon Mobil Corporation primarily operates in the United States, Canada, Europe, Africa, the Asia Pacific, the Middle East, Russia/Caspian region, and South America. The company was formerly known as Exxon Corporation and changed its name to Exxon Mobil Corporation in November 1999. Exxon Mobil Corporation was founded in 1870 and is based in Irving, Texas.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In todayís market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Dow Chemical Co.,DOW
After Hours: 17.53 Down 0.03 (0.17%) 7:23PM ET
Last Trade: 17.56
Day's Range: 16.95 - 18.11
52wk Range: 5.89 - 39.99
Volume: 19,420,219
The Dow Chemical Company engages in the manufacture and sale of chemicals, plastic materials, agricultural, and other specialized products and services worldwide. The company operates in six segments: Performance Plastics, Performance Chemicals, Agricultural Sciences, Basic Plastics, Basic Chemicals, and Hydrocarbons and Energy. The Performance Plastics segment provides automotive products, building solutions, epoxy resins, intermediates and specialty resins, polyurethanes and polyurethane systems, specialty plastics and elastomers, and technology licensing and catalyst products. The Performance Chemicals segment offers polymers, latex, and specialty chemicals. The Agricultural Sciences segment provides pest management, agricultural, and crop biotechnology products and solutions. The Basic Plastics segment offers polyethylene, polypropylene, and polystyrene resins. The Basic Chemicals segment provides chemicals, such as acids, alcohols, caustic soda, chlorine, chloroform, and other chemicals; and ethylene oxide/ethylene glycol chemicals. The Hydrocarbons and Energy segment procures fuels, natural gas liquids, and crude oil-based raw materials, as well as supplies monomers, power, and steam.
---
Johnson & Johnson,JNJ
After Hours: 55.66 0.00 (0.00%) 6:05PM ET
Last Trade: 55.66
Day's Range: 55.22 - 56.25
52wk Range: 46.25 - 72.76
Volume: 13,263,830
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and womens health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSONS, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company's Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohns disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain
---
Do not invest in these stocks because we mentioned them in this release. We never include our picks in these news releases. This is just to alert you to our service. Our alerts are saved for our subscribers. To receive Alerts on the stock we feel are going to move, sign up for our free alert service.
Visit WhisperfromWallStreet.com to sign up for your FREE subscription or download our free Windows Vista or iGoogle gadget for instant alerts direct to your desktop or iGoogle page.
If you are a public company looking to generate investor awareness for your company please contact us at info@WhisperfromWallStreet.com.
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com 585-301-7700
